• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vigil Neuroscience Inc.

    2/14/23 4:10:03 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIGL alert in real time by email
    SC 13G 1 d466805dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No.     )*

    Under the Securities Exchange Act of 1934

     

     

    Vigil Neuroscience, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    92673K108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 92673K108

    Page 2 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Hatteras Venture Partners VI, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      PN


    CUSIP No. 92673K108

    Page 3 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Hatteras Venture Advisors VI, LLC

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      North Carolina

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      OO


    CUSIP No. 92673K108

    Page 4 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      John C. Crumpler

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 5 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Clay B. Thorp

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      3,000

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      3,000

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,565,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 6 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Douglas Reed

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 7 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Robert Ingram

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 8 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Christy Shaffer

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 9 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      John M. Dial

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 10 of 16

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Jeffrey Terrell

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,562,578

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,562,578

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,562,578

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.4%

    12.  

      Type of Reporting Person

     

      IN


    CUSIP No. 92673K108

    Page 11 of 16

     

    Item 1(a)

    Name of Issuer

    Vigil Neuroscience, Inc. (the “Issuer”)

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices

    1 Broadway, 7th Floor, Suite 07-300, Cambridge, Massachusetts 02142

     

    Item 2(a)

    Name of Person Filing

    This Schedule 13G is being filed by:

    Hatteras Venture Partners VI, L.P. (“HVP VI”)

    Hatteras Venture Advisors VI, LLC (“HVA VI”)

    John C. Crumpler

    Clay B. Thorp

    Douglas Reed

    Robert Ingram

    Christy Shaffer

    John M. Dial

    Jeffrey Terrell

    (collectively, the “Reporting Persons”).

     

    Item 2(b)

    Address of Principal Business Office, or if none, Residence

    280 S. Mangum Street, Suite 350, Durham, North Carolina 27701.

     

    Item 2(c)

    Citizenship

    The Reporting Persons are citizens of:

    HVP VI — Delaware

    HVA VI — North Carolina

    John C. Crumpler — USA

    Clay B. Thorp — USA

    Douglas Reed — USA

    Robert Ingram — USA

    Christy Shaffer — USA

    John M. Dial — USA

    Jeffrey Terrell — USA

     

    Item 2(d)

    Title of Class of Securities

    Common Stock, par value $0.0001 per share (“Common Stock”)

     

    Item 2(e)

    CUSIP Number

    92673K108


    CUSIP No. 92673K108

    Page 12 of 16

     

    Item 3.

    Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)

    Not Applicable

     

    Item 4.

    Ownership

    (a) The Reporting Persons, with the exception of Mr. Thorp who beneficially owns an aggregate of 1,565,578 shares of the Issuer’s Common Stock due to shares he holds personally, are the beneficial owners of an aggregate of 1,562,578 shares of Common Stock, which represents 4.4% of the Issuer’s outstanding Common Stock based upon 35,581,091 shares outstanding on October 31, 2022 as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2022 as filed with the Securities and Exchange Commission on November 10, 2022.

    HVA VI is the general partner of HVP VI. The shares are held directly by HVP VI. The shares held by HVP VI are indirectly held by the individual managing members of the general partners, HVA VI (the “GP Managing Members”). The GP Managing Members are John C. Crumpler, Clay B. Thorp, Douglas Reed, Robert Ingram, Christy Shaffer, John M. Dial and Jeffrey Terrell. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP VI.

    (b) Percent of class:

    HVP VI — 4.4%

    HVA VI — 4.4%

    John C. Crumpler — 4.4%

    Clay B. Thorp — 4.4%

    Douglas Reed — 4.4%

    Robert Ingram — 4.4%

    Christy Shaffer — 4.4%

    John M. Dial — 4.4%

    Jeffrey Terrell — 4.4%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote:

    HVP VI — 1,562,578

    HVA VI — 1,562,578

    John C. Crumpler — 1,562,578

    Clay B. Thorp — 1,565,578

    Douglas Reed — 1,562,578

    Robert Ingram — 1,562,578

    Christy Shaffer — 1,562,578

    John M. Dial — 1,562,578

    Jeffrey Terrell — 1,562,578

    (iii) Sole power to dispose or to direct the disposition of: 0


    CUSIP No. 92673K108

    Page 13 of 16

     

    (iv) Shared power to dispose or to direct the disposition of:

    HVP VI — 1,562,578

    HVA VI— 1,562,578

    John C. Crumpler — 1,562,578

    Clay B. Thorp — 1,565,578

    Douglas Reed — 1,562,578

    Robert Ingram — 1,562,578

    Christy Shaffer — 1,562,578

    John M. Dial — 1,562,578

    Jeffrey Terrell — 1,562,578

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    By signing below each of the undersigned certifies that, to the best of his, her or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Exhibit Index

    Exhibit A –Agreement Regarding the Joint Filing of Schedule 13G


    CUSIP No. 92673K108

    Page 14 of 16

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2023

     

    HATTERAS VENTURE PARTNERS VI, L.P.
    By:   Hatteras Venture Advisors VI, LLC, its general partner
    By:  

    /s/ Clay B. Thorp

      Manager
    HATTERAS VENTURE ADVISORS VI, LLC
    By:  

    /s/ Clay B. Thorp

      Manager

     

    /s/ John C. Crumpler

    John C. Crumpler

    /s/ Clay B. Thorp

    Clay B. Thorp

    /s/ Douglas Reed

    Douglas Reed

    /s/ Robert Ingram

    Robert Ingram

    /s/ Christy Shaffer

    Christy Shaffer

    /s/ John M. Dial

    John M. Dial

    /s/ Jeffrey Terrell

    Jeffrey Terrell
    Get the next $VIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIGL

    DatePrice TargetRatingAnalyst
    12/4/2024Outperform
    William Blair
    12/19/2023$13.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    10/18/2023$23.00Mkt Outperform
    JMP Securities
    3/31/2023$15.00Buy
    Mizuho
    9/16/2022$19.00Outperform
    Wedbush
    8/29/2022$24.00Buy
    H.C. Wainwright
    2/1/2022$17.00Equal-Weight
    Morgan Stanley
    2/1/2022$23.00Buy
    Guggenheim
    More analyst ratings

    $VIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

      – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma

      5/7/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

      - Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Dis

      4/2/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Budd Haeberlein Samantha L. bought $20,520 worth of shares (12,000 units at $1.71) (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:44:11 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,400 worth of shares (5,000 units at $1.68), increasing direct ownership by 2% to 222,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:42:45 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,350 worth of Common Stock (5,000 units at $1.67), increasing direct ownership by 2% to 217,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/18/24 5:51:48 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 4:19:18 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 10:00:07 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vigil Neuroscience Inc.

      SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      10/9/24 6:22:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Kaufmann Petra

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      3/4/25 5:09:51 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bruhn Suzanne Louise

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      3/4/25 5:09:31 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Ziolkowski Jennifer Lynn

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      3/4/25 5:09:35 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Vigil Neuroscience

      William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform

      12/4/24 7:51:48 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

      12/19/23 7:39:43 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Vigil Neuroscience with a new price target

      JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00

      10/18/23 7:41:08 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:36:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:35:49 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:34:29 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Financials

    Live finance-specific insights

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

      VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r

      11/2/22 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

      Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – February 13, 2025 – Augustine Therapeutics ("Augustine" or "the Company"), a preclinical-stage biotechnology company focused on innovative therapies for neuromuscular, neurodegenerative and cardiometabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announc

      2/13/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

      Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem

      6/26/24 1:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

      – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or

      5/7/24 4:05:00 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care